HC Wainwright Raises Earnings Estimates for Pharming Group

Key Points

• HC Wainwright raised Pharming Group’s FY2027 EPS estimate to $0.54 from $0.50, while maintaining a Buy rating and $37 price target.
• Pharming reported quarterly EPS of $0.02, missing the $0.06 consensus estimate; analyst sentiment remains mixed, with a consensus Hold rating and average price target of $38.67.
• Shares opened at $9.95, near the company’s 52-week low of $9.62, while MAC Alpha Capital Management acquired approximately 3.03% of the company, valued at about $29.8 million.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) - Research analysts at HC Wainwright upped their FY2027 earnings estimates for Pharming Group in a report released on Wednesday, September 30th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn $0.54 per share for the year, up from their prior estimate of $0.50. HC Wainwright has a "Buy" rating and a $37.00 price target on the stock. The consensus estimate for Pharming Group's current full-year earnings is $0.22 per share.

Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%.

Several other equities analysts have also weighed in on PHAR. Weiss Ratings restated a "sell (d)" rating on shares of Pharming Group in a research note on Friday, August 7th. Zacks Research lowered Pharming Group from a "hold" rating to a "strong sell" rating in a report on Friday, July 31st. Canaccord Genuity Group set a $38.00 price objective on Pharming Group in a research report on Wednesday, September 23rd. Finally, Oppenheimer reaffirmed an "outperform" rating on shares of Pharming Group in a research note on Thursday, July 30th. Three equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $38.67.

Pharming Group Trading Down 0.4%

Shares of Pharming Group stock opened at $9.95 on Friday. The firm has a 50-day simple moving average of $11.21 and a two-hundred day simple moving average of $13.30. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.31 and a current ratio of 3.01. Pharming Group has a fifty-two week low of $9.62 and a fifty-two week high of $21.34. The company has a market cap of $704.26 million, a P/E ratio of 82.92 and a beta of -0.04.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. MAC Alpha Capital Management LP bought a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,148,144 shares of the company's stock, valued at approximately $29,838,000. Pharming Group comprises about 6.0% of MAC Alpha Capital Management LP's portfolio, making the stock its 2nd biggest holding. MAC Alpha Capital Management LP owned approximately 3.03% of Pharming Group as of its most recent SEC filing. Institutional investors and hedge funds own 0.03% of the company's stock.

About Pharming Group

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands, focused on developing and commercializing treatments for rare diseases. The company uses its expertise in protein replacement therapies and other biotechnology platforms to address conditions with limited treatment options.

Pharming's principal product is Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause severe swelling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.